Data Availability StatementData writing is not applicable to this article as no datasets were generated or analyzed during the current study. into the development of effective vaccines against COVID-19. [1, 2]. These are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry. Their genome size is usually relatively large for RNA viruses, between 27 and 34 kB [3]. Coronaviruses infect mammals and birds causing varied symptoms such as respiratory tract disease and diarrhea. In humans, coronavirus infections have been shown to be potentially lethal. This is the case of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) coronaviruses. In 2002C2003, the world experienced what would become the first of a series of lethal coronavirus infections. The disease denominated severe acute respiratory syndrome (SARS) would be characterized by high fever, developing into shortness of breath and pneumonia [4] eventually. While it began with southern China, the condition would trigger 8096 situations afterwards, leading to 774 fatalities in 26 countries [5]. Despite initiatives from the technological community, no vaccine became commercially obtainable and SARS situations ceased to become reported from 2004 [4]. In 2012 September, the globe experienced the introduction of the center East respiratory symptoms (MERS) coronavirus. Started in Saudi Arabia, the infectious disease is normally characterized by light respiratory symptoms, but these could become severe respiratory system distress death and symptoms [6]. The disease provides affected 27 countries, leading to 2494 situations and 858 fatalities [7]. MERS situations are still getting reported but no main outbreak continues to be announced since 2015 [8]. As regarding SARS, no industrial vaccine is normally designed for MERS. Known reasons for having less business and effective vaccines for MERS and SARS are varied. In the entire case of MERS, chances are which the vaccine advancement was delayed due to the scarcity of ideal and cost-effective little animal versions during pre-clinical experimentation. Furthermore, it is possible a vaccine is not delivered due to the low curiosity about purchasing a vaccine for an illness that has created fairly low and geographically centralized situations (weighed against other even more global and consistent infectious diseases such as for example influenza, HIV and tuberculosis). This last aspect may have added to having less a vaccine for SARS also, in the feeling that GSK598809 it had been considered pointless to keep purchasing a vaccine for an illness whose situations ceased to be reported in 2004. Coronavirus GSK598809 disease 2019 (COVID-19) is definitely a present pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The 1st cases were reported from Wuhan, China, in December 2019 [9, 10]. According to the World Health Business (WHO), the disease has been reported in 213 countries and territories as of April 11, 2020, with evidence of ongoing local transmission GSK598809 [11]. According to the same business, you will find 1,669,595 confirmed instances and 106,138 deaths associated with the disease. Symptoms of COVID-19 are slight and include fever, cough and shortness of breath. Nevertheless, the disease might progress into severe pneumonia and multi-organ failure mainly in elders and people with other underlying diseases [9, 12]. Although no vaccines are commercially available for Rabbit Polyclonal to TRMT11 SARS and MERS, recent and GSK598809 current vaccine development attempts against these diseases might be of high value for the development of an effective vaccine for COVID-19. The present review aims to describe these attempts. Furthermore, we describe the possible implications of creating an effective vaccine.